Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP32914
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AP32914 is an **active metabolite of mobocertinib**, a tyrosine kinase inhibitor developed for the treatment of non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. AP32914 is formed via CYP3A-mediated metabolism of mobocertinib in humans. Like mobocertinib and its other primary metabolite AP32960, AP32914 exhibits similar potency and mechanism of action, contributing to the clinical efficacy of mobocertinib. Data regarding its individual pharmacological effects, beyond its profile as an active metabolite, is limited. AP32914 has been studied primarily in the context of mobocertinib pharmacokinetic and metabolism studies, where it is measured in plasma, whole blood, urine, and feces following oral administration of mobocertinib[1][2][3][5].
- Other names
- AP32914AP-32914AP 32914
02
Targets
HER2 exon 20 ins (Human epidermal growth factor receptor 2 (HER2) exon 20 insertion mutants)EGFR ex20ins (Epidermal growth factor receptor exon 20 mutant)
Beyond the preview
Go deeper on AP32914.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP32914.